NCT07077512View on ClinicalTrials.gov

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

July 15, 2027

Conditions
Large B Cell Diffuse LymphomaMantle Cell Lymphoma (MCL)Follicular Lymphoma ( FL)
Interventions
DRUG

Autoleucel (Relmacabtagene Autoleucel)

Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).

DRUG

Sintilimab (PD-1 inhibitor)

Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.

Trial Locations (3)

51000

Sun Yat-sen Universitiy Cancer Center, Guangzhou

510060

Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

510632

Guangzhou overseas Chinese hospital, Guangzhou

All Listed Sponsors
collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangzhou Overseas Chinese Hospital,Guangdong

UNKNOWN

lead

Sun Yat-sen University

OTHER